Trulieve Cannabis’ (TRLV) Overweight Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald reissued their overweight rating on shares of Trulieve Cannabis (NYSE:TRLV) in a research note published on Monday morning,Benzinga reports. Cantor Fitzgerald currently has a $15.00 price objective on the stock.

Other equities research analysts have also recently issued research reports about the stock. Wall Street Zen cut shares of Trulieve Cannabis from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Trulieve Cannabis in a research note on Friday, September 11th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $15.00.

Trulieve Cannabis Stock Performance

Shares of TRLV stock opened at $11.55 on Monday. The firm’s fifty day simple moving average is $11.21. The company has a current ratio of 5.94, a quick ratio of 3.98 and a debt-to-equity ratio of 0.45. Trulieve Cannabis has a 12 month low of $4.62 and a 12 month high of $13.28.

Trulieve Cannabis (NYSE:TRLV) last issued its quarterly earnings results on Friday, August 7th. The company reported $0.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.06 by $0.05. Trulieve Cannabis had a negative net margin of 41.55% and a negative return on equity of 4.24%. The company had revenue of $271.00 million during the quarter, compared to analyst estimates of $268.82 million. As a group, research analysts expect that Trulieve Cannabis will post 0.31 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in TRLV. StoneX Group Inc. purchased a new stake in Trulieve Cannabis in the 3rd quarter worth approximately $341,000. Commonwealth Equity Services LLC bought a new stake in Trulieve Cannabis during the 3rd quarter worth approximately $242,000. Partners Wealth Management LLC purchased a new position in Trulieve Cannabis during the third quarter valued at approximately $504,000. North Star Investment Management Corp. purchased a new position in Trulieve Cannabis during the third quarter valued at approximately $28,000. Finally, Marion Wealth Management bought a new position in shares of Trulieve Cannabis in the third quarter worth approximately $109,000.

About Trulieve Cannabis

Trulieve Cannabis Corp. is a vertically integrated cannabis company that cultivates, processes and sells medical and adult-use cannabis products. Its offerings include flower, pre-rolls, concentrates, vaporizers, edibles, tinctures, capsules and topical products, sold through retail dispensaries and other approved channels under brands such as Trulieve, Cultivar Collection, Muse, Roll One and Alchemy.

Founded in 2015, Trulieve initially built its business around Florida’s medical cannabis market and later expanded into additional U.S.